Maintenance therapy for multiple myeloma

Postinduction maintenance therapy in both young and elderly patients with newly diagnosed multiple myeloma is beyond doubt. The article presents the results of clinical studies to evaluate the effectiveness of proteasome inhibitors and immunomodulatory drugs in postinduction maintenance therapy for patients with multiple myeloma of different ages. An analysis of the effectiveness of bortezomib, ixazomib, lenalidomide and thalidomide is presented. It has been shown that maintenance therapy significantly increases the survival rate of patients with multiple myeloma, including at high risk. The article is of particular interest to hematologists, therapists, clinical residents and students of medical universities.